http://rdf.ncbi.nlm.nih.gov/pubchem/patent/IE-950090-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f166b76c106acecc9c1ce7ad47e063f |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-34 |
| filingDate | 1995-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b46f5dc5c3eb5e2f2765df867e0de955 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d45136d30bbe442ae3fab32698f0a26f |
| publicationDate | 1996-08-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | IE-950090-A1 |
| titleOfInvention | Pharmaceutical composition |
| abstract | A combination product comprising Ranitidine hydrochloride Form 1 and a bismuth compound and solvates of the combination product. Ranitidine hydrochloride is the accepted name N-£2-£££5-£Dimethyl-amino)methyl|2-furany1|methyl|thio|ethyl for/-N'-methyl-2-n/itro-1, /1-ethenediamine-hydrochloride. It exists in two different crystalline forms, designated as Form I and Form II. The mixture contains 0,1425 mol of Ranitidine hydrochloride Form 1 and 0,046 mol bismuth subsalicylate. (molar ratio 1: 3:1 bismuth subsalicylate/Ranitidine hydrochloride Form 1). |
| priorityDate | 1995-02-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 56.